Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
NDRA vs NEO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NEO Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–3 Matrix Metrics)
NEO Overall Winner
6-Pillar Tally: NDRA 2 – 4 NEO
Matrix Metrics: NDRA 3 – 5 NEO
As of Nov 17, 2026, NeoGenomics, Inc. (NEO) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas NEO carries 35.6/100 (SELL) at $15.49 (N/M Forward P/E, -5.5% operating margin).
- Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. NEO 35.6/100 SELL), NEO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-5.5% vs. 0.0% operating margin) and revenue trajectory (+11.4% vs. +0.0% YoY).
- Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile NEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NDRA vs NEO
NDRA
ENDRA Life Sciences Inc. Common Stock
$4.42
+0.23% 1D
Market Cap
$6.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.71β · 48% Vol
Unified Composite Score
44.7
HOLD
Tech 35.0
Fund 46.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
NEO
Head-to-Head Winner
NeoGenomics, Inc.
$15.49
+0.55% 1D
Market Cap
$2.1B
TTM Revenue
$788M
Forward P/E
N/M
Beta / 30D Vol
1.23β · 47% Vol
Unified Composite Score
35.6
SELL
Tech 23.0
Fund 44.0
Flow 58.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (NDRA 2 – 4 NEO)
1. Valuation Multiples
NEO
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
2.09x
EV / Revenue
N/M
3.0x
2. Growth & Scale
NEO
Revenue Growth (YoY)
+0.0%
+11.4%
Earnings Growth (YoY)
+0.0%
+130.6%
TTM Revenue (USD)
N/A
$788M
Market Cap
$6.6M
$2.1B
3. Profitability & Quality
NDRA
Gross Margin
N/A
44.8%
Operating Margin
0.0%
-5.5%
Net Profit Margin
0.0%
-4.1%
Return on Equity (ROE)
-152.0%
-3.9%
4. Balance Sheet & Cash Flow
NDRA
Cash Generation (TTM)
-$8.0M
-$29M
Cash Flow Margin
N/A
-3.6%
Net Cash / Leverage
$104,744 Net Debt (0.26x D/E)
$310M Net Debt (0.56x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
NEO
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
100.0% (14th %ile)
Put/Call OI Skew
N/A
0.12x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
NEO
OpEx & R&D Intensity
N/A
50.3% of Rev ($396M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NDRA (3) vs NEO (5)| Institutional Metric | NDRA | NEO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.6M | $2.1B | NEO | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | +11.4% | NEO | |
| Operating Margin (TTM) | 0.0% | -5.5% | NDRA | |
| Net Profit Margin | 0.0% | -4.1% | NDRA | |
| Return on Equity (ROE) | -152.0% | -3.9% | NEO | |
| 52-Week Range Position | 37% ($3–$7) | 64% ($7–$20) | NEO | |
| Beta / 30D Volatility | 0.71β · 48% Vol | 1.23β · 47% Vol | NEO | |
| Unified Institutional Score | 44.7 / 100 (HOLD) | 35.6 / 100 (SELL) | NDRA | |
| Trailing 12M Revenue (USD) | N/A | $788M | Scale | |
| Gross Profit Margin (TTM) | N/A | 44.8% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 2.09x PEG · 3.0x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$8.0M ($104,744 Net Debt (0.26x D/E)) | -$29M ($310M Net Debt (0.56x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
NDRA +0.7 pp
3M Horizon
NDRA +1.08 pp
6M Horizon
NEO +102.41 pp
1Y Horizon
NEO +83.06 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NDRA Revenue | NEO Revenue | NDRA Op. Margin | NEO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $280M | -146080.5% | 3.6% | NEO |
| FY2019 | N/A | $410M | N/A | 3.2% | NEO |
| FY2020 | N/A | $440M | N/A | -3.1% | NEO |
| FY2021 | N/A | $480M | N/A | -24.5% | NEO |
| FY2022 | N/A | $510M | N/A | -30.9% | NEO |
| FY2023 | N/A | $590M | N/A | -18.2% | NEO |
| FY2024 | N/A | $660M | N/A | -13.9% | NEO |
| FY2025 | N/A | $730M | N/A | -15.9% | NEO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NDRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NEO
CONSOLIDATION
Current IV
100.0%
IV Percentile
14th %ile
Put/Call OI Skew
0.12x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NDRA Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
NEO Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
50.3% of Rev ($396M)
90D Engineering Disclosures
0 Published
Investor FAQ NDRA vs NEO Key Questions & Quantitative Answers
As of Nov 17, 2026, NeoGenomics, Inc. (NEO) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas NEO carries 35.6/100 (SELL) at $15.49 (N/M Forward P/E, -5.5% operating margin). Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. NEO 35.6/100 SELL), NEO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-5.5% vs. 0.0% operating margin) and revenue trajectory (+11.4% vs. +0.0% YoY). Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile NEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NEO leads the Growth & Scale pillar: NDRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NEO at +11.4% YoY revenue growth and +130.6% YoY earnings growth on $788M TTM revenue (44.8% gross margin, -5.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NDRA cumulative revenue shifted N/A while NEO shifted +160.7%. In operating R&D and SG&A reinvestment, NDRA deploys N/A (0 90-day corporate R&D disclosures) versus 50.3% of Rev ($396M) (0 disclosures) for NEO.
NEO screens cheaper on headline valuation multiples. NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NEO trades at N/M Forward P/E, N/M Trailing P/E, 2.09x PEG, and 3.0x EV/Revenue (-3.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NDRA (-152.0% ROE) versus NEO (-3.9% ROE) capital efficiency.
In options market volatility and institutional positioning, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk). By comparison, NEO carries 100.0% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.12x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.23β · 47% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NEO vs NDRA · Reverse Pair
NEO vs VCYT
· Sector Peer
NEO vs NVCR
· Sector Peer
NEO vs GKOS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking